The Utah Mammoth announced today the signing of forward Nick Schmaltz to an eight-year contract extension with an average annual value (AAV) of $8 million. “There was never a doubt that Utah is where ...

LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported ...

Were REGENXBIO's Risk Warnings About AAV Gene Therapy Adequate?NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP examines the adequacy of REGENXBIO, Inc.'s (NASDAQ: RGNX) risk disclosures to investors ...

Rocket Pharmaceuticals, Inc. ( RCKT) TD Cowen 46th Annual Health Care Conference March 2, 2026 11:10 AM EST ...

QuTEM and Boston University collaborate to provide localized, high-speed AAV analysis for North American gene therapy ...

Favorable early safety and initial efficacy data from BEST1 program highlighted at premier gathering of global retinal ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...

Atamyo Therapeutics, a biotechnology company specializing in the development of next-generation gene therapies for limb-girdle muscular dystrophy (LGMD), announced at the MDA (Muscular Dystrophy ...

Links to the conference webcasts may be accessed on Opus Genetcs’ website under the Investors section: Events.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root ...

Webcasts of the presentations will be available here on the Investors section of the Company’s website. About Rocket Pharmaceuticals, Inc. Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully ...

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or dose-limiting ...